A Novel Phenotype of Junctional Epidermolysis Bullosa with Transient Skin Fragility and Predominant Ocular Involvement Responsive to Human Amniotic Membrane Eyedrops
Authors:
- Daniele CastigliaDCDaniele Castiglia
- Paola FortugnoPFPaola Fortugno
- Angelo Giuseppe CondorelliACAngelo Giuseppe Condorelli
- Sabina BarresiSBSabina Barresi
- Naomi De LucaNLNaomi De Luca
- Simone PizziSPSimone Pizzi
- Iria NeriINIria Neri
- Claudio GrazianoCGClaudio Graziano
- Diletta TrojanDTDiletta Trojan
- Diego PonzinDPDiego Ponzin
- Sabrina RossiSRSabrina Rossi
- Giovanna ZambrunoGZGiovanna Zambruno
Open Access
Abstract
Junctional epidermolysis bullosa (JEB) is a clinically and genetically heterogeneous skin fragility disorder frequently caused by mutations in genes encoding the epithelial laminin isoform, laminin-332. JEB patients also present mucosal involvement, including painful corneal lesions. Recurrent corneal abrasions may lead to corneal opacities and visual impairment. Current treatments are merely supportive. We report a novel JEB phenotype distinguished by the complete resolution of skin fragility in infancy and persistent ocular involvement with unremitting and painful corneal abrasions. Biallelic LAMB3 mutations c.3052-5C>G and c.3492_3493delCG were identified as the molecular basis for this phenotype, with one mutation being a hypomorphic splice variant that allows residual wild-type laminin-332 production. The reduced laminin-332 level was associated with impaired keratinocyte adhesion. Then, we also investigated the therapeutic power of a human amniotic membrane (AM) eyedrop preparation for corneal lesions. AM were isolated from placenta donors, according to a procedure preserving the AM biological characteristics as a tissue, and confirmed to contain laminin-332. We found that AM eyedrop preparation could restore keratinocyte adhesion in an in vitro assay. Of note, AM eyedrop administration to the patient resulted in long-lasting remission of her ocular manifestations. Our findings suggest that AM eyedrops could represent an effective, non-invasive, simple-to-handle treatment for corneal lesions in patients with JEB and possibly other EB forms.Keywords
Funding Information
- Italian Ministry of Health (CCR-2017-23669081)
This publication has 49 references indexed in Scilit:
- Laminin 332 processing impacts cellular behaviorCell Adhesion & Migration, 2013
- Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosaJournal of Medical Genetics, 2011
- Amniotic membrane extraction solution for ocular chemical burnsClinical & Experimental Ophthalmology, 2009
- Amnia for intractable skin ulcers with recessive dystrophic epidermolysis bullosa: Report of three casesThe Journal of Dermatology, 2007
- Amniotic Membrane Transplantation for Treatment of Symblepharon in a Patient With Recessive Dystrophic Epidermolysis BullosaCornea, 2006
- Laminin-5 Mutational Analysis in an Italian Cohort of Patients with Junctional Epidermolysis BullosaJournal of Investigative Dermatology, 2004
- Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs non-Herlitz phenotypesHuman Genetics, 2001
- Reduced Expression of the Epithelial Adhesion Ligand Laminin 5 in the Skin Causes Intradermal Tissue SeparationJournal of Biological Chemistry, 2001
- The Assembly of Laminin-5 SubunitsJournal of Biological Chemistry, 1995
- Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing.Journal of Cell Biology, 1995